mRNA |
Sorafenib |
CCLE |
pan-cancer |
AAC |
0.11 |
0.02 |
mRNA |
decitabine |
CTRPv2 |
pan-cancer |
AAC |
-0.061 |
0.02 |
mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.079 |
0.02 |
mRNA |
CAY10618 |
CTRPv2 |
pan-cancer |
AAC |
-0.076 |
0.02 |
mRNA |
tigecycline |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.02 |
mRNA |
selumetinib:BRD-A02303741 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.076 |
0.02 |
mRNA |
BRD-K16130065 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
0.03 |
mRNA |
tretinoin:carboplatin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.072 |
0.03 |
mRNA |
azacitidine |
CTRPv2 |
pan-cancer |
AAC |
0.077 |
0.03 |
mRNA |
selumetinib:MK-2206 (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.073 |
0.03 |